Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX ...

Apogee touts positive data for atopic dermatitis drug

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.

Apogee Therapeutics to Announce Phase 2 APEX Trial Results for APG777 on July 7, 2025

Apogee Therapeutics will announce Phase 2 APEX trial data for APG777 on July 7, 2025, with a follow-up conference call.

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX ...

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for…

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Webcast to be held Monday, July 7th at 8:00 a.m. ET...

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 - Apogee Therapeutics (NASDAQ:APGE)

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications,…

Positive 16-Week Findings Identified for APG777 in Patients with Atopic Dermatitis

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.